ClinicalTrials.gg
CompletedNCT01715129DKP 3M SCUpdated Dec 9, 2019Results posted

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

A Phase 3 interventional study of Triptorelin Pamoate 11.25mg in Prostate Cancer, sponsored by Ipsen. Completed at 12 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-09.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
13th of 28
126 · median 120
Started
2013
the only one that year
Phase 3
12 of 28
2 open now
Registered
14th of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 12 in phase 3, and was the 14th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven locally advanced or prostate cancer who are suitable for androgen deprivation therapy
  • Male aged ≥18 years old
  • Screening testosterone level of >125 ng/dL
  • of greater than 12 months in the judgement of the Investigator
  • (ECOG) performance status of 0-1
  • Willing to give signed freely
  • Able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Prior hormonal therapy for prostate cancer
  • Prior surgery or radiotherapy of prostate cancer with curative intent unless disease is verified by a rising prostate specific antigen (PSA) concentration on follow up (elevated PSA values on last two tests conducted at least a month apart) and the patient is eligible for androgen deprivation therapy
  • Presence or history of any other except for non melanoma skin cancer adequately treated at least 2 years before study entry
  • Painful local bone lesions or spinal lesions which may lead to compression
  • History of myocardial infarction, percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass graft, Class III/IV congestive heart failure, cerebrovascular accident, , or limb claudication at rest, within six months prior to start of study treatment and ongoing symptomatic dysrhythmias, unstable angina, uncontrolled hypertension, and untreated atrial or uncontrolled ventricular arrhythmias
  • Any condition in opinion of the Investigator, including other active or latent infections, medical or psychiatric conditions, or the presence of laboratory abnormalities, which could confound the ability to interpret data from the study, compromises the objective of the study or places the patient at unacceptable risk if he participates in the study
  • Abnormal haematological, hepatic or renal functions:

    • \<9 g/dL, ≤1.5 x 10\^9/L or ≤100 x 10\^9/L
    • Serum creatinine ≥1.5 times the (ULN)
    • or alanine aminotransferase >2.5 times the ULN
  • Known to the study treatment, to any of its
  • Known active use of recreational drug or alcohol dependence in the opinion of the Investigator
  • Any current use or use within six months prior to start of treatment, of medications which are known to affect the metabolism and/or secretion of androgenic hormones: e.g. ketoconazole, aminoglutethimide, oestrogens, and progesterone
  • Use of systemic (inhaled corticosteroids and topical application of corticosteroids are permitted)
  • Aged ≥90 years for the main study and ≥80 years for those included in the pharmacokinetic (PK) patient population
  • Participation in any other study or receipt of any compound in the 30 days (or five times the elimination half life if this is longer) prior to study entry
  • Any skin or other condition that may preclude s.c. injection administration
  • Known brain or epidural .
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    11.25mg

    11.25mg, SC on Day 1 and Day 92

    Drug: Triptorelin Pamoate 11.25mg

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183

    Percentage of subjects castrated (i.e. with serum testosterone \<50 ng/dL or 1.735 nmol/L, using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and the proportion with castration maintained at Day 183 (after receiving 2 S.C. administrations of triptorelin pamoate, three months apart); they were calculated along with their respective 95% confidence intervals (CI) using exact methods on the ITT population at Day 29 and on the initially castrated (IC) population at Day 183

    Time frame: At Day 29 and 183

Secondary outcomes

  1. Percentage of Subjects Demonstrating Castration Before Administration of the Second Dose

    Percentage of subjects demonstrating castration at Day 92 (before administration of the second dose) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.

    Time frame: At Day 92

  2. Probability of Testosterone <50 ng/dL

    Probability of testosterone \<50 ng/dL from Day 29 to Day 183 was assessed as a secondary endpoint using the time to event from first administration date to first observed (and subsequently confirmed if assessment not performed at end of study or early withdrawal visits) serum testosterone level ≥50 ng/dL or ≥1.735 nmol/L at or after Day 29, assessed using the LC-MS/MS Method and Missing Data imputed by immunoassay method Kaplan-Meier Analysis. LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry

    Time frame: Day 29 through Day 183

  3. Percentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 95

    Percentage of subjects demonstrating castration at Day 95 (3-4 days after administration of the second dose to assess the suppression of acute-on-chronic effect following the second administration) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.

    Time frame: Day 95

  4. Time to Achieve Castration (Tcast)

    Time to castration (Tcast) from first administration date until first observed serum testosterone level \<50 ng/dL or \<1.735 nmol/L evaluated using the immunoassay method only (i.e. defined as the number of days between the injection time at Day 1 and castration achievement)

    Time frame: Up to Day 36

  5. Plasma Triptorelin Levels (Cmin)

    Minimal triptorelin plasma concentration at the end of each dosage interval just before the next dose injection (Cmin) for Days 92 and 183 were assessed.

    Time frame: At Day 92 and 183

  6. Percentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects

    Serum PSA level was presented throughout the study using descriptive statistics displaying raw values, change from Baseline and percentage change from Baseline at each visit in all subjects from the ITT population only. Additionally, the PSA level was described in subjects with elevated PSA levels (i.e. \>4 ng/mL) at study entry, and the proportion of subjects with normal PSA levels (i.e. \[0-4\] ng/mL) at Day 183 compared to Baseline was presented.

    Time frame: From Day 1 (Baseline) to Day 183 (End of study)

  7. Percentage of Subjects With Normal and Abnormal PSA Levels at Day 183 (End of Study Visit)

    0-4 ng/mL (normal PSA value) \>4 ng/mL (abnormal PSA levels)

    Time frame: At Day 183

  8. Clinically Apparent Tumor Progression

    Tumour progression was recorded according to the Investigator's clinical judgement, considering the PSA levels and any other indications of disease; the clinical confirmation might be supplemented by radiological or other investigations or scans if required. The lack of clinically apparent tumour progression was assessed at Day 92 (prior to administration of the second dose) and Day 183 (end of study visit).

    Time frame: Day 92 and 183

  9. Percentage of Subjects With Adverse Events

    Time frame: Up to Day 183

  10. Time to Cmax (Tmax) of Triptorelin

    Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1

  11. Peak Plasma Concentration Value (Cmax) of Triptorelin

    Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1

  12. Area Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin

    Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1

  13. Cmin of Triptorelin in Subset of 18 Subjects

    Time frame: At Day 92 and 183

07

Results

Posted Oct 28, 2015

Participant flow

Participant flow — Overall Study
MilestoneTriptorelin Pamoate
Started126
Completed117
Not completed9
Withdrew: Adverse event, fatal1
Withdrew: Lack of efficacy3
Withdrew: Protocol violation1
Withdrew: Consent withdrawn2
Withdrew: Lost to follow-up1
Withdrew: Other1

Outcome measures

PrimaryPercentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183

Percentage of subjects castrated (i.e. with serum testosterone \<50 ng/dL or 1.735 nmol/L, using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and the proportion with castration maintained at Day 183 (after receiving 2 S.C. administrations of triptorelin pamoate, three months apart); they were calculated along with their respective 95% confidence intervals (CI) using exact methods on the ITT population at Day 29 and on the initially castrated (IC) population at Day 183

Time frame:
At Day 29 and 183
Reported as:
Number · Percentage of subjects
Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183
Percentage of subjectsTriptorelin Pamoate
Day 29 (N=126)97.6 (93.2 to 99.5)
Day 183 (N=119)96.6 (91.6 to 99.1)
SecondaryPercentage of Subjects Demonstrating Castration Before Administration of the Second Dose

Percentage of subjects demonstrating castration at Day 92 (before administration of the second dose) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.

Time frame:
At Day 92
Reported as:
Number · Percentage of subjects
Percentage of Subjects Demonstrating Castration Before Administration of the Second Dose
Percentage of subjectsTriptorelin Pamoate
Percentage of Subjects Demonstrating Castration Before Administration of the Second Dose99.2 (95.4 to 100)
SecondaryProbability of Testosterone <50 ng/dL

Probability of testosterone \<50 ng/dL from Day 29 to Day 183 was assessed as a secondary endpoint using the time to event from first administration date to first observed (and subsequently confirmed if assessment not performed at end of study or early withdrawal visits) serum testosterone level ≥50 ng/dL or ≥1.735 nmol/L at or after Day 29, assessed using the LC-MS/MS Method and Missing Data imputed by immunoassay method Kaplan-Meier Analysis. LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry

Time frame:
Day 29 through Day 183
Reported as:
Number · Proportion of subjects
Probability of Testosterone <50 ng/dL
Proportion of subjectsTriptorelin Pamoate
Probability of Testosterone <50 ng/dL0.96 (0.92 to 0.99)
SecondaryPercentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 95

Percentage of subjects demonstrating castration at Day 95 (3-4 days after administration of the second dose to assess the suppression of acute-on-chronic effect following the second administration) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.

Time frame:
Day 95
Reported as:
Number · Percentage of subjects
Percentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 95
Percentage of subjectsTriptorelin Pamoate
Percentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 9598.3 (94.1 to 99.8)
SecondaryTime to Achieve Castration (Tcast)

Time to castration (Tcast) from first administration date until first observed serum testosterone level \<50 ng/dL or \<1.735 nmol/L evaluated using the immunoassay method only (i.e. defined as the number of days between the injection time at Day 1 and castration achievement)

Time frame:
Up to Day 36
Reported as:
Median · Day
Time to Achieve Castration (Tcast)
DayTriptorelin Pamoate
Time to Achieve Castration (Tcast)22 (22 to 23)
SecondaryPlasma Triptorelin Levels (Cmin)

Minimal triptorelin plasma concentration at the end of each dosage interval just before the next dose injection (Cmin) for Days 92 and 183 were assessed.

Time frame:
At Day 92 and 183
Reported as:
Mean · ng/mL
Plasma Triptorelin Levels (Cmin)
ng/mLTriptorelin Pamoate
Day 920.062 ± 0.031
Day 183 (N=117)0.049 ± 0.027
SecondaryPercentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects

Serum PSA level was presented throughout the study using descriptive statistics displaying raw values, change from Baseline and percentage change from Baseline at each visit in all subjects from the ITT population only. Additionally, the PSA level was described in subjects with elevated PSA levels (i.e. \>4 ng/mL) at study entry, and the proportion of subjects with normal PSA levels (i.e. \[0-4\] ng/mL) at Day 183 compared to Baseline was presented.

Time frame:
From Day 1 (Baseline) to Day 183 (End of study)
Reported as:
Mean · Percentage Change
Percentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects
Percentage ChangeTriptorelin Pamoate
Percentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects-85.503 ± 42.410
SecondaryPercentage of Subjects With Normal and Abnormal PSA Levels at Day 183 (End of Study Visit)

0-4 ng/mL (normal PSA value) \>4 ng/mL (abnormal PSA levels)

Time frame:
At Day 183
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Normal and Abnormal PSA Levels at Day 183 (End of Study Visit)
Percentage of subjectsTriptorelin Pamoate
End of Study (0-4 ng/mL)84.6
End of Study (>4 ng/mL)15.4
SecondaryClinically Apparent Tumor Progression

Tumour progression was recorded according to the Investigator's clinical judgement, considering the PSA levels and any other indications of disease; the clinical confirmation might be supplemented by radiological or other investigations or scans if required. The lack of clinically apparent tumour progression was assessed at Day 92 (prior to administration of the second dose) and Day 183 (end of study visit).

Time frame:
Day 92 and 183
Reported as:
Number · participants
Clinically Apparent Tumor Progression
participantsTriptorelin Pamoate
Day 92: Non Progressive Disease122
Day 92: Progressive Disease0
Day 183: Non Progressive Disease114
Day 183: Progressive Disease3
SecondaryPercentage of Subjects With Adverse Events
Time frame:
Up to Day 183
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Adverse Events
Percentage of subjectsTriptorelin Pamoate
Any Adverse Events35.7
Any Serious Adverse Events (SAEs)4.8
Any Treatment Emergent Adverse Events (TEAEs)35.7
TEAEs Leading to Withdrawal0.8
TEAEs Leading to Death0.8
Maximum Grade NCI-CTC of TEAEs: Grade 50.8
Maximum Grade NCI-CTC of TEAEs: Grade 40
Maximum Grade NCI-CTC of TEAEs: Grade 34.0
Maximum Grade NCI-CTC of TEAEs: Grade 213.5
Maximum Grade NCI-CTC of TEAEs: Grade 127.8
Most serious causality of TEAEs: Related21.4
Most serious causality of TEAEs: Not related26.2
SecondaryTime to Cmax (Tmax) of Triptorelin
Time frame:
At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Reported as:
Median · Hours
Time to Cmax (Tmax) of Triptorelin
HoursTriptorelin Pamoate
Time to Cmax (Tmax) of Triptorelin4.5 (1.01 to 24)
SecondaryPeak Plasma Concentration Value (Cmax) of Triptorelin
Time frame:
At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Reported as:
Mean · ng/mL
Peak Plasma Concentration Value (Cmax) of Triptorelin
ng/mLTriptorelin Pamoate
Peak Plasma Concentration Value (Cmax) of Triptorelin18.58 ± 7.35
SecondaryArea Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin
Time frame:
At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Reported as:
Mean · h*ng/mL
Area Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin
h*ng/mLTriptorelin Pamoate
Area Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin304.6 ± 103.7
SecondaryCmin of Triptorelin in Subset of 18 Subjects
Time frame:
At Day 92 and 183
Reported as:
Mean · ng/mL
Cmin of Triptorelin in Subset of 18 Subjects
ng/mLTriptorelin Pamoate
Day 92 (N=14)0.078 ± 0.038
Day 183 (N=18)0.062 ± 0.023

Adverse events

Collected over Up to Day 183. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin Pamoate 11.25 mg—6/126 (4.8%)45/126 (35.7%)
Most frequent serious events
Most frequent serious events
EventTriptorelin Pamoate 11.25 mg
PneumoniaInfections and infestations2/126
Fibula FractureInjury, poisoning and procedural complications1/126
Cardiac FailureCardiac disorders1/126
Myocardial infarctionCardiac disorders1/126
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/126
AnaemiaBlood and lymphatic system disorders1/126
Most frequent other events
Showing 10 of 58
Most frequent other events
EventTriptorelin Pamoate 11.25 mg
Hot FlushVascular disorders13/126
Weight IncreasedInvestigations12/126
Weight DecreasedInvestigations7/126
HypertensionVascular disorders6/126
HeadacheNervous system disorders4/126
Erectile DysfunctionReproductive system and breast disorders3/126
HyperhidrosisSkin and subcutaneous tissue disorders3/126
Oedema PeripheralGeneral disorders2/126
Breast PainReproductive system and breast disorders2/126
FallInjury, poisoning and procedural complications2/126

Baseline characteristics

Age, Continuous
Age, Continuous(years)Triptorelin Pamoate
Mean70.4 ± 7.3
Sex/Gender, Customized
Sex/Gender, Customized(participants)Triptorelin Pamoate
Male126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Triptorelin Pamoate
Caucasian / White120
Missing6
Height
Height(cm)Triptorelin Pamoate
Mean172.2 ± 6.7
Weight
Weight(kg)Triptorelin Pamoate
Mean80.6 ± 12.8
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Triptorelin Pamoate
Mean27.16 ± 3.96
Prostate Specific Antigen (PSA)
Prostate Specific Antigen (PSA)(ng/mL)Triptorelin Pamoate
Mean133.53 ± 385.60
08

Study locations

12 sites
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Shumen, Bulgaria
  • Varna, Bulgaria
  • Suresnes, France
  • Daugavpils, Latvia
  • Riga, Latvia
  • Kutno, Poland
  • Warsaw, Poland
  • Wroclaw, Poland
  • Bucharest, Romania
  • Craiova, Romania
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Oct 26, 2012
Start
Jan 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 28, 2015
Last update
Dec 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01715129
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Oct 26, 2012
Start date
Jan 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 28, 2015
Last update
Dec 9, 2019

Study contacts

Medical Director, Uro-Oncology
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion